These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 29374616

  • 21. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
    De Giorgio R, Zucco FM, Chiarioni G, Mercadante S, Corazziari ES, Caraceni A, Odetti P, Giusti R, Marinangeli F, Pinto C.
    Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
    [Abstract] [Full Text] [Related]

  • 22. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M, Tack J.
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [Abstract] [Full Text] [Related]

  • 23. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC.
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [Abstract] [Full Text] [Related]

  • 24. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
    Lawson R, Ryan J, King F, Goh JW, Tichy E, Marsh K.
    Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
    [Abstract] [Full Text] [Related]

  • 25. An update on the use of pharmacotherapy for opioid-induced bowel dysfunction.
    Mousavi T, Nikfar S, Abdollahi M.
    Expert Opin Pharmacother; 2023 Feb; 24(3):359-375. PubMed ID: 36548911
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials.
    McNicol E, Boyce DB, Schumann R, Carr D.
    Pain Med; 2008 Sep; 9(6):634-59. PubMed ID: 18828197
    [Abstract] [Full Text] [Related]

  • 27. Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain.
    Viscusi ER.
    Clin J Pain; 2019 Feb; 35(2):174-188. PubMed ID: 30289777
    [Abstract] [Full Text] [Related]

  • 28. Alvimopan.
    Neary P, Delaney CP.
    Expert Opin Investig Drugs; 2005 Apr; 14(4):479-88. PubMed ID: 15882122
    [Abstract] [Full Text] [Related]

  • 29. The Management of Opioid-Induced Constipation in Cancer and Advanced Illness: A Meta-Analysis.
    Jesuyajolu DA, Abubakar AK, Kowe T, Ogunlade S, Abioye AI, Tangeman J, Latuga N, Omotayo MO.
    J Pain Symptom Manage; 2024 Apr; 67(4):e285-e297. PubMed ID: 38092261
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
    Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC.
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):831-844. PubMed ID: 31474542
    [Abstract] [Full Text] [Related]

  • 32. Mu-opioid antagonists for opioid-induced bowel dysfunction.
    McNicol ED, Boyce D, Schumann R, Carr DB.
    Cochrane Database Syst Rev; 2008 Apr 16; (2):CD006332. PubMed ID: 18425947
    [Abstract] [Full Text] [Related]

  • 33. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis.
    Ford AC, Suares NC.
    Gut; 2011 Feb 16; 60(2):209-18. PubMed ID: 21205879
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological Profile of Naldemedine, a Peripherally Acting μ-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol.
    Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y, Hasegawa M.
    J Pharmacol Exp Ther; 2020 Jun 16; 373(3):438-444. PubMed ID: 32169839
    [Abstract] [Full Text] [Related]

  • 35. Naloxegol: a review of its use in patients with opioid-induced constipation.
    Garnock-Jones KP.
    Drugs; 2015 Mar 16; 75(4):419-25. PubMed ID: 25666542
    [Abstract] [Full Text] [Related]

  • 36. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
    Leppert W.
    Adv Ther; 2010 Oct 16; 27(10):714-30. PubMed ID: 20799006
    [Abstract] [Full Text] [Related]

  • 37. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
    Pergolizzi JV, Christo PJ, LeQuang JA, Magnusson P.
    Drug Des Devel Ther; 2020 Oct 16; 14():1009-1025. PubMed ID: 32210534
    [Abstract] [Full Text] [Related]

  • 38. New developments in the treatment of opioid-induced gastrointestinal symptoms.
    Pannemans J, Vanuytsel T, Tack J.
    United European Gastroenterol J; 2018 Oct 16; 6(8):1126-1135. PubMed ID: 30288274
    [Abstract] [Full Text] [Related]

  • 39. Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation.
    Chokhavatia S, John ES, Bridgeman MB, Dixit D.
    Drugs Aging; 2016 Aug 16; 33(8):557-74. PubMed ID: 27417446
    [Abstract] [Full Text] [Related]

  • 40. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M, Naidoo K, Akobeng AK, Thomas AG.
    Evid Based Child Health; 2013 Jan 16; 8(1):57-109. PubMed ID: 23878124
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.